Objective: This study was performed to evaluate the overall survival and the change in treatment modalities in patients with uterine endometrial cancer in Korea. Methods: From January 1990 to March 2005, medical records of 740 patients with endometrial cancer in nine hospitals were reviewed. The overall survival was determined supported by the death statistics of Korea National Statistical Office. Results: The mean age of patients was 51.5 years (range: 21-82 years). The mean gravidity and parity were 3.3 and 2.1 (range: 0-18, 0-9), respectively. The most common stage, grade and histological type at diagnosis were FIGO stage I, grade 1 and endometrioid adenocarcinoma (76.5%, 56.4% and 87.2%), respectively. The main treatment modalities was surgery on stage I (59.8%), surgery- adjuvant radiotherapy on stage II (55.1%), surgery-adjuvant radiotherapy or surgery-adjuvant chemoradiation on stage Ⅲ (38.3%) and surgery-adjuvant chemotherapy on stage IV (55.6%). The preferred treatment modality was surgery only on grade 1 (69.0%) and surgery-adjuvant radiotherapy on grade 2-3 (43.4% and 53.2%). Surgery had been the most common method of therapy before 1998 but its prevalence gradually decreased. As a result, surgery-adjuvant radiotherapy and surgery-adjuvant chemotherapy were most widely performed in 2004-2005 and surgery-adjuvant chemoradiation also increased more than a twofold. The overall 5 years survival rate (5YSR) for all 740 patients was 81.3%. The overall 5YSR of stage I was 89.0%. The overall 5YSR of grade 1, grade 2, grade 3 were 96.0%, 92.0%, 80.0%. Before 1998, the survival rate was 77.0%. Since then it increased to 83-88% and in 2000-2001 it increased to 88.0%, and it was the highest survival rate. Conclusion: The survival rate of endometrial cancer has been improving for the past 15 years and the method of treatment is also being changed currently. In order to improve the survival rate of endometrial cancer, a close investigation including genetic and environmental factors of the pathophysiology of endometrial cancer along with the epidemiology of risk factors, should be carried out.
[1]
N. Park,et al.
Contemporary trends of endometrial cancer in Korean women
,
2005
.
[2]
R. Kudo,et al.
JGOG2033: Randomized phase III trial of whole pelvic radiotherapy vs cisplatin-based chemotherapy in patients with intermediate risk endometrial carcinoma
,
2005
.
[3]
J. Ferlay,et al.
Global Cancer Statistics, 2002
,
2005,
CA: a cancer journal for clinicians.
[4]
Jesse Hickerson.
Endometrial carcinoma: treatment and outcomes in the regional hospital setting.
,
2003,
American journal of obstetrics and gynecology.
[5]
H. Hirte,et al.
Current status and future innovations of hormonal agents, chemotherapy and investigational agents in endometrial cancer
,
2002,
Current opinion in obstetrics & gynecology.
[6]
Jacques Ferlay,et al.
Estimates of the worldwide incidence of 25 major cancers in 1990
,
1999,
International journal of cancer.
[7]
R. Coates,et al.
Racial differences in tumor grade among women with endometrial cancer.
,
1995,
Gynecologic oncology.
[8]
R. Hoover,et al.
Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study.
,
1992,
American journal of obstetrics and gynecology.
[9]
N. Weiss,et al.
Increasing incidence of endometrial cancer in the United States.
,
1976,
The New England journal of medicine.
[10]
Richard Doll,et al.
Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices
,
1975,
International journal of cancer.